Previously, naked VEGF‐A mRNA in citrate saline solution (without LNPs as carriers) has been applied in clinical trials in patients with cardiovascular disease,[58, 60] and type 2 diabetes.[57] However, currently, there is no safe carrier that can deliver VEGF‐A mRNA to the heart. This evidence concerns the gene VEGFA and cardiovascular disorder.